SG11201702558VA - Treatment of cancer with immune stimulators - Google Patents

Treatment of cancer with immune stimulators

Info

Publication number: SG11201702558VA
Authority: SG; Singapore
Prior art keywords: cancer; treatment; immune stimulators; stimulators; immune
Prior art date: 2014-10-21

Application number

SG11201702558VA

Inventor

Robert S King

Cynthia Tuthill

Friedhelm Blobel

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-21

Filing date

2015-10-21

Publication date

2017-05-30

2015-10-21 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2017-05-30 Publication of SG11201702558VA publication Critical patent/SG11201702558VA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

SG11201702558VA 2014-10-21 2015-10-21 Treatment of cancer with immune stimulators SG11201702558VA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462066862P	2014-10-21	2014-10-21
US201562215433P	2015-09-08	2015-09-08
PCT/US2015/056609 WO2016064969A1 (en)	2014-10-21	2015-10-21	Treatment of cancer with immune stimulators

Publications (1)

Publication Number	Publication Date
SG11201702558VA true SG11201702558VA (en)	2017-05-30

Family

ID=55748164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201702558VA SG11201702558VA (en)	2014-10-21	2015-10-21	Treatment of cancer with immune stimulators

Country Status (16)

Country	Link
US (4)	US9724395B2 (en)
EP (2)	EP3209321B1 (en)
JP (2)	JP6821560B2 (en)
KR (1)	KR102589557B1 (en)
CN (2)	CN113855806A (en)
AU (1)	AU2015335979B2 (en)
BR (1)	BR112017007817A2 (en)
CA (1)	CA2962451C (en)
ES (1)	ES2882080T3 (en)
IL (1)	IL251761B (en)
MX (1)	MX2017005134A (en)
RU (2)	RU2020142556A (en)
SG (1)	SG11201702558VA (en)
TW (2)	TWI683667B (en)
WO (1)	WO2016064969A1 (en)
ZA (1)	ZA201702111B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2020142556A (en)	2014-10-21	2021-02-12	Сайклон Фармасьютикалз Интернешнл Лтд.	METHOD FOR TREATING CANCER OR ITS METASTASIS WITH THYMOSIN-ALPHA PEPTIDE AND PROTEIN PROTEIN INHIBITOR OF PROGRAMMED CELL DEATH-1 (PD-1)
CA3002381A1 (en) *	2015-10-21	2017-04-27	Teclison Limited	Compositions and methods for immune-mediated cancer therapy
US20200237904A1 (en) *	2017-01-26	2020-07-30	Immune Therapeutics Inc.	Methods and Compositions Useful for Treating Cancer
CN109793891A (en) *	2017-11-17	2019-05-24	韩震	Application of the polypeptide compound in the adjuvant that preparation improves therapeutic antibodies curative effect and composition and preparation method thereof
WO2019149279A1 (en) *	2018-02-02	2019-08-08	科济生物医药（上海）有限公司	Combination of cellular immunotherapy
KR20200078312A (en)	2018-12-21	2020-07-01	한미약품 주식회사	Novel immune suppressing IL-2 analogs
JP2023515247A (en)	2020-03-31	2023-04-12	ハンミファーマシューティカルカンパニーリミテッド	Novel immunologically active interleukin-2 analogues
CN111821424B (en) *	2020-07-21	2023-03-31	广东海洋大学深圳研究院	Application of thymosin and derivative thereof and medicament for treating depression
CN112023027B (en) *	2020-07-21	2023-03-14	广东海洋大学	Application of thymosin or derivative thereof and medicine for treating anhedonia type depression
AR125263A1 (en)	2021-03-31	2023-06-28	Hanmi Pharm Ind Co Ltd	NEW IMMUNOSTIMULANT IL-2 ANALOG CONJUGATE AND ITS METHOD OF PREPARATION
CA3235940A1 (en) *	2021-10-21	2023-04-27	Jeffrey A. BACHA	Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
DE2604845A1 (en)	1976-02-07	1977-08-18	Knoll Ag	NEW PIPERAZINE DERIVATIVES
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AR036993A1 (en)	2001-04-02	2004-10-20	Wyeth Corp	USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
BRPI0518571A2 (en) *	2004-12-06	2008-11-25	Sciclone Pharmaceuticals Inc	alpha thymosine peptides as cancer vaccine adjuvants
CA2607147C (en)	2005-05-09	2018-07-17	Ono Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN101300024A (en)	2005-11-08	2008-11-05	米德列斯公司	Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
CA2657821A1 (en)	2006-07-21	2008-01-24	Gilead Sciences, Inc.	Aza-peptide protease inhibitors
US20080300166A1 (en) *	2007-06-01	2008-12-04	Sciclone Pharmaceuticals, Inc.	Treatment of Melanoma with Alpha Thymosin Peptides
JP5393665B2 (en)	2007-07-06	2014-01-22	ギリアードサイエンシーズ，インコーポレイテッド	Modulator of pharmacokinetic properties of therapeutic agents
US20090021740A1 (en) *	2007-07-17	2009-01-22	Chung Yuan Christian University	Optical sensor and method for measuring blood gas
CA2709027A1 (en) *	2007-12-12	2009-06-18	Sciclone Pharmaceuticals, Inc.	Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
CN101945664A (en) *	2007-12-13	2011-01-12	赛生制药有限公司	Combined therapy melanoma with alpha thymosin peptides and inhibitors of kinases
CA2708168A1 (en)	2007-12-14	2009-06-25	Sciclone Pharmaceuticals, Inc.	Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2307050A4 (en)	2008-07-04	2012-07-25	Ono Pharmaceutical Co	Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
CA2736816C (en)	2008-09-12	2018-05-22	Isis Innovation Limited	Pd-1 specific antibodies and uses thereof
EP3133086B1 (en)	2008-09-26	2018-08-01	Dana-Farber Cancer Institute, Inc.	Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
EP2393835B1 (en)	2009-02-09	2017-04-05	Université d'Aix-Marseille	Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN101591397A (en) *	2009-07-01	2009-12-02	石继红	Long-acting thymosin alpha 1 α's 1 is recombinant expressed and uses thereof
CA2826875A1 (en) *	2011-02-09	2012-08-16	Sciclone Pharmaceuticals, Inc.	Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CA2833636A1 (en)	2011-04-20	2012-10-26	Amplimmune, Inc.	Antibodies and other molecules that bind b7-h1 and pd-1
JP5790345B2 (en) *	2011-09-07	2015-10-07	株式会社リコー	Image processing apparatus, image processing method, program, and image processing system
CA2881851C (en) *	2012-08-30	2021-01-26	Amgen Inc.	A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
RU2020142556A (en)	2014-10-21	2021-02-12	Сайклон Фармасьютикалз Интернешнл Лтд.	METHOD FOR TREATING CANCER OR ITS METASTASIS WITH THYMOSIN-ALPHA PEPTIDE AND PROTEIN PROTEIN INHIBITOR OF PROGRAMMED CELL DEATH-1 (PD-1)

2015
- 2015-10-21 RU RU2020142556A patent/RU2020142556A/en unknown
- 2015-10-21 RU RU2017117194A patent/RU2740288C2/en active
- 2015-10-21 TW TW104134583A patent/TWI683667B/en active
- 2015-10-21 CA CA2962451A patent/CA2962451C/en active Active
- 2015-10-21 SG SG11201702558VA patent/SG11201702558VA/en unknown
- 2015-10-21 BR BR112017007817A patent/BR112017007817A2/en active Search and Examination
- 2015-10-21 MX MX2017005134A patent/MX2017005134A/en unknown
- 2015-10-21 KR KR1020177011825A patent/KR102589557B1/en active IP Right Grant
- 2015-10-21 EP EP15852092.4A patent/EP3209321B1/en active Active
- 2015-10-21 CN CN202111207032.5A patent/CN113855806A/en active Pending
- 2015-10-21 WO PCT/US2015/056609 patent/WO2016064969A1/en active Application Filing
- 2015-10-21 JP JP2017519663A patent/JP6821560B2/en active Active
- 2015-10-21 TW TW108147603A patent/TWI749433B/en active
- 2015-10-21 ES ES15852092T patent/ES2882080T3/en active Active
- 2015-10-21 CN CN201580057457.9A patent/CN107148279B/en active Active
- 2015-10-21 EP EP21178724.7A patent/EP3943101A1/en active Pending
- 2015-10-21 AU AU2015335979A patent/AU2015335979B2/en active Active
- 2015-10-21 US US14/918,675 patent/US9724395B2/en active Active
2017
- 2017-03-27 ZA ZA2017/02111A patent/ZA201702111B/en unknown
- 2017-04-18 IL IL251761A patent/IL251761B/en active IP Right Grant
- 2017-07-05 US US15/641,550 patent/US20180161399A1/en not_active Abandoned
2020
- 2020-01-07 US US16/736,211 patent/US11571465B2/en active Active
2021
- 2021-01-06 JP JP2021000764A patent/JP7175334B2/en active Active
2022
- 2022-12-12 US US18/064,793 patent/US20230285513A1/en active Pending

Also Published As

Publication number	Publication date
CN113855806A (en)	2021-12-31
CA2962451C (en)	2023-01-17
EP3209321A4 (en)	2018-10-31
US20180161399A1 (en)	2018-06-14
JP7175334B2 (en)	2022-11-18
US20230285513A1 (en)	2023-09-14
EP3209321B1 (en)	2021-06-23
US20160106812A1 (en)	2016-04-21
JP2021088557A (en)	2021-06-10
RU2740288C2 (en)	2021-01-12
RU2017117194A (en)	2018-11-22
IL251761A0 (en)	2017-06-29
ES2882080T3 (en)	2021-12-01
MX2017005134A (en)	2018-02-12
US9724395B2 (en)	2017-08-08
JP2018501192A (en)	2018-01-18
BR112017007817A2 (en)	2017-12-19
CA2962451A1 (en)	2016-04-28
RU2020142556A (en)	2021-02-12
IL251761B (en)	2020-09-30
JP6821560B2 (en)	2021-01-27
TWI683667B (en)	2020-02-01
EP3943101A1 (en)	2022-01-26
RU2017117194A3 (en)	2019-04-09
KR102589557B1 (en)	2023-10-16
US11571465B2 (en)	2023-02-07
US20200289618A1 (en)	2020-09-17
AU2015335979A1 (en)	2017-04-20
CN107148279B (en)	2021-09-03
WO2016064969A1 (en)	2016-04-28
TW202034946A (en)	2020-10-01
TW201615209A (en)	2016-05-01
EP3209321A1 (en)	2017-08-30
ZA201702111B (en)	2019-06-26
CN107148279A (en)	2017-09-08
KR20170070091A (en)	2017-06-21
TWI749433B (en)	2021-12-11
AU2015335979B2 (en)	2021-05-20

Publication	Publication Date	Title
IL250677A0 (en)	2017-03-30	Treatment of cancers using anti-nkg2a agents
FI3851537T3 (en)	2024-03-21	Treatment of hyperbilirubinemia
GB201701673D0 (en)	2017-03-15	Methods of well treatment
IL251761A0 (en)	2017-06-29	Treatment of cancer with immune stimulators
IL261959A (en)	2018-10-31	Treatment of cancer with tg02
SI3122358T1 (en)	2021-04-30	Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
HK1231561A1 (en)	2017-12-22	Cancer treatment
HK1231386A1 (en)	2017-12-22	Treatment of immune disorders
IL263835A (en)	2019-02-03	Exosome-guided treatment of cancer
GB201416832D0 (en)	2014-11-05	Methods of treatment
HK1249866A1 (en)	2018-11-16	Methods of treatment with taselisib
GB201409363D0 (en)	2014-07-09	Skin cancer treatment
GB201408297D0 (en)	2014-06-25	Treatment of cancer
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201417456D0 (en)	2014-11-19	Treatment of cancer
GB201407837D0 (en)	2014-06-18	Methods of cancer therapy
GB201622214D0 (en)	2017-02-08	treatment of cancer
GB201409362D0 (en)	2014-07-09	Treatment of cancer
GB201604621D0 (en)	2016-05-04	Treatment of cancer
GB201604293D0 (en)	2016-04-27	Treatment of cancer
GB201405449D0 (en)	2014-05-07	Treatment of cancer
GB201405075D0 (en)	2014-05-07	Treatment of cancer
GB201512723D0 (en)	2015-08-26	Treatment of cancer
PT3851537T (en)	2024-03-06	Treatment of hyperbilirubinemia
GB201417465D0 (en)	2014-11-19	Treatment of cancers